Original Research

Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain

Schlueter M, Finn E, Díaz S, Dilla T, Inciarte-Mundo J, Fakhouri W

ClinicoEconomics and Outcomes Research 2019, 11:395-403

Published Date: 6 June 2019